Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry...
All content for Pharma and BioTech Daily is the property of Pharma and BioTech News and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry...
Promising Results for Atebimetinib in Pancreatic Cancer & Other Pharma Updates
Pharma and BioTech Daily
1 week ago
Promising Results for Atebimetinib in Pancreatic Cancer & Other Pharma Updates
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.## Immuneering's drug atebimetinib has shown promising results in doubling overall survival in pancreatic cancer patients after nine months. Truist analysts have deemed the results encouraging, although some unknowns remain in the data. Immuneering plans to initiate a registrational trial for atebimetinib later this year. ## In other news, Lilly has halted a mid...
Pharma and BioTech Daily
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry...
